Indivior tightens grip on opioid addiction market with Sublocade’s new FDA approval

The FDA has given Indivior the OK to sell its monthly injectable version of Suboxone, shoring up the company’s tenuous hold on the opioid addiction market as competition looms near. The drug, to be marketed as Sublocade (RBP-6000), is a monthly injection of buprenorphine, which contains a mild opioid to help stymie withdrawal for addicts … Continue reading Indivior tightens grip on opioid addiction market with Sublocade’s new FDA approval